Dr Apolo talks to ecancerv at ASCO GU 2016 about the use of avelumab (MSB0010718C) for metastatic urothelial carcinoma (mUC).

Avelumab is a fully human anti-PD-L1 IgG1 antibody being investigated in multiple clinical trials.

This study reported the safety and clinical activity of avelumab as a second-line therapy in patients with metastatic urothelial carcinoma  based on level of PD-L1 expression.

Avelumab showed an acceptable safety profile and had clinical activity in patients with mUC.

There was a trend towards higher overall response rate and prolonged progression free survival rate at 12 weeks in patients with PD-L1 mUC.

Further analyses of PD-L1 expression and clinical activity of avelumab in urothelial carcinoma are ongoing.